At Home NeuroCare Leverage the new NeuroCare AI-driven virtual clinic to extend Nexalin TES therapy to Alzheimer's, mood disorders, TBI and PTSD. Target hospitals, health systems, senior care providers and telehealth platforms to integrate TES with remote monitoring and care pathways. The UC San Diego partnership and at home Gen-3 Halo headset trial data can support scalable deployment and payer discussions.

Strategic Collaborations Strategic collaborations with academia and government present sales opportunities in clinical trials, defense and veterans health. Engage UC San Diego, potential VA/hospital networks, and the Military & Government Advisory Board to access larger procurement programs, grants and reimbursement pilots.

Leadership for Growth Recent leadership appointments (CFO Justin Van Fleet; General Wesley K. Clark joining the Military & Government Advisory Board) signal readiness to scale, manage pricing, compliance and enterprise contracts. This enhances credibility for hospitals, clinics and government entities pursuing large-scale deployments.

Regulatory Momentum Regulatory posture shows low-risk classification for clinical trials and a safety-focused profile, enabling conversations with hospitals and payers. Focus on expanding clinical evidence, regulatory milestones and real-world data to accelerate adoption and reimbursement opportunities.

Market Differentiation Strong tech differentiation with noninvasive TES and a patented waveform that influences neurochemistry, positioned to appeal to mental health, sleep and neurorehabilitation markets. Combine device hardware with digital care via NeuroCare and home use trials to win partnerships with neurology, psychiatry, sleep clinics, elder care and outpatient rehab providers.